Sort
10,766 grants matching “checkpoint inhibitor”
Simultaneous Radiotherapy with PD-1 and IDO1 Blockade for Overcoming Immune Suppression in Glioblastoma
$255,555Derek Alan Wainwright · Northwestern University At Chicago · P50 · FY2018 · CA
Development Therapeutics Branch Clinical Trials
$255,288Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Targeting Wee1 in Myc driven Medulloblasoma
$255,118Rajeev Vibhakar · University Of Colorado Denver · R01 · FY2019 · NS
Targeting Wee1 in Myc driven Medulloblasoma
$255,118Rajeev Vibhakar · University Of Colorado Denver · R01 · FY2017 · NS
Targeting Wee1 in Myc driven Medulloblasoma
$255,118Rajeev Vibhakar · University Of Colorado Denver · R01 · FY2016 · NS
Targeting JAB1 Oncogenic Function in Breast Cancer
$255,009Francois X Claret · University Of Tx Md Anderson Can Ctr · R01 · FY2009 · CA
Targeting JAB1 Oncogenic Function in Breast Cancer
$255,009Francois X Claret · University Of Tx Md Anderson Can Ctr · R01 · FY2008 · CA
Targeting JAB1 Oncogenic Function in Breast Cancer
$255,009Francois X Claret · University Of Tx Md Anderson Can Ctr · R01 · FY2010 · CA
Targeting JAB1 Oncogenic Function in Breast Cancer
$255,009Francois X Claret · University Of Tx Md Anderson Can Ctr · R01 · FY2007 · CA
Targeting Wee1 in Myc driven Medulloblasoma
$254,913Rajeev Vibhakar · University Of Colorado Denver · R01 · FY2015 · NS
Pathway inhibitors in Lymphomas
$254,824Mark Roschewski · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Targeting ROS enzymes in immunosuppressive myeloid cells to enhance immunotherapy
$254,788Tracy W Liu · West Virginia University · P20 · FY2025 · GM
The Houston Center for Acquired Resistance Research (H-CARR)
$254,772Jeffrey Nicholas Myers · University Of Tx Md Anderson Can Ctr · U54 · FY2023 · CA
Project 1 - Dioxin-like Compounds Suppress IgM Responses by Targeting CD5+ (Innate-like) B cells, which can Serve as a Biomarker of Susceptibility to Environmental AHR Ligands
$254,506Norbert E Kaminski · Michigan State University · P42 · FY2025 · ES
PSGL-1, a New Player in the Immune Checkpoint Landscape
$254,475Linda Mac Pherson Bradley · Sanford Burnham Prebys Medical Discovery Institute · R21 · FY2017 · CA
RNF125 controls melanoma response to B-RAF inhibitor and immune checkpoint therapy
$254,475Hyungsoo Kim · Sanford Burnham Prebys Medical Discovery Institute · R21 · FY2015 · CA
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
$254,475Linda Mac Pherson Bradley · Sanford Burnham Prebys Medical Discovery Institute · R21 · FY2017 · CA
MALT1 as a rational therapeutic target in African American ancestry patients with DLBCL
$254,250Roberta Zappasodi · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
Role of polycystin-1 in centrosome duplication and cell cycle control
$254,250Gabriele Luca Gusella · Icahn School Of Medicine At Mount Sinai · R01 · FY2009 · DK
Role of polycystin-1 in centrosome duplication and cell cycle control
$254,250Gabriele Luca Gusella · Icahn School Of Medicine At Mount Sinai · R01 · FY2008 · DK
Mechanism of the Spindle Assembly Checkpoint Control
$254,123Guowei Fang · Stanford University · R01 · FY2006 · GM
G2 Checkpoint Function in Human Fibroblasts
$253,850University Of North Carolina Chapel Hill · R01 · FY2004 · CA
G2 Checkpoint Function in Human Fibroblasts
$253,850University Of North Carolina Chapel Hill · R01 · FY2003 · CA
G2 Checkpoint Function in Human Fibroblasts
$253,850University Of North Carolina Chapel Hill · R01 · FY2005 · CA
New tools for imaging and theranostics in inflammation and cancer
$253,741Sangeeta Ray · Ut Southwestern Medical Center · P41 · FY2025 · EB